Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 6.5M | 33.1% |
| Net Income | -5.1M | 40.1% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 32M | 16.3% |
| Total Liabilities | 23M | 3.5% |
| Total Equity | 7.9M | 35.1% |
| Shares Outstanding | 6.6M | 14.1% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -5.7M | 17.9% |
EPS
Financial Highlights for vTv Therapeutics in Q1 '25
Operating Expenses for this period were 6.5M, showing a 33.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -5.1M, showing a -40.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
vTv Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
